Masaru Kanekiyo

This paper designs de novo protein nanoparticles with integrated functional motifs, demonstrating their ability to form structured assemblies and elicit immune responses in mice.

The paper isolates glycan-reactive antibodies from HIV-1 vaccine trial participants and finds they neutralize diverse HIV strains and show broad cross-reactivity against other pathogens.

This paper designs self-assembling protein nanoparticle vaccines using AlphaFold2 predictions, demonstrating atomic-level accuracy and potent immune responses in mice.

This study shows that macaques can elicit human-like broadly neutralizing antibodies against influenza HA stem regions, with similar immunogenetic and structural features.

This study identifies human antibodies that broadly inhibit influenza neuraminidase by mimicking its substrate through structural convergence and water-mediated interactions.

Stabilizing H5 HA mutations enhance neutralizing antibody responses by shifting epitope targeting toward the receptor binding site in vaccinated mice.

The paper shows that genetic variation in human immunoglobulin genes affects antibody responses to influenza HA, informing vaccine design to cover diverse populations.

This paper introduces MAGE, a model that generates paired human antibody sequences against specific targets, validated against SARS-CoV-2, H5N1, and RSV-A.

The paper maps antibody sequences to antigen specificity across multiple viral antigens, identifying convergent sequence features in antiviral B cells.

This study examines how prior H2 influenza exposure influences polyclonal antibody responses to H2N2 vaccination, showing differences in epitope targeting between H2-exposed and H2-naive individuals.

Designed trimers matched to viral glycoprotein termini yielded tetrahedral, octahedral and icosahedral nanoparticles with cryo-EM-verified structures that display native-like HIV Env, influenza HA and RSV F.